Onconova Therapeutics is on the verge of something big here. Early Access Programs like the one this news surrounds are great news. They suggest that early data is so positive that there is a strong chance for approval ahead.
Not only does the program mean that ONTX has a strong chance of receiving full regulatory approval, it also means that the company will soon generate revenue fromt he drug. While only select patients will have access to the drug, every time it is used, the company will generate revenue.
Moreover, these types of programs allow the company to build out its data on the drug. After all, the data that we have to date is clinical data. When the program starts, we will start to see real-world data coming in, likely further supporting the approval of the drug.
All in all, today is a big day for ONTX and its investors.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join or free mailing list below to receive real-time news alerts!